Idiopathic Pulmonary Fibrosis With Progressive Disease Therapeutics
1. Esbriet patent expiration
Treatment: Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; D...
ESBRIET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420674 | LEGACY PHARMA | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(1 year, 11 months from now) | |
| US7696326 | LEGACY PHARMA | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
Dec, 2027
(1 year, 11 months from now) | |
| US9561217 | LEGACY PHARMA | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
Jan, 2022
(3 years ago) | |
| US7696236 | LEGACY PHARMA | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(1 year, 11 months from now) | |
| US7988994 | LEGACY PHARMA | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(8 months from now) | |
| US8013002 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
| US8778947 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Aug, 2033
(7 years from now) | |
| US7767225 | LEGACY PHARMA | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(8 months from now) | |
| US7767700 | LEGACY PHARMA | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(1 year, 11 months from now) | |
| US7816383 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
| US8754109 | LEGACY PHARMA | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(4 years from now) | |
| US8318780 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
| US7910610 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
| US7566729 | LEGACY PHARMA | Modifying pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US8383150 | LEGACY PHARMA | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
May, 2028
(2 years from now) | |
| US8084475 | LEGACY PHARMA | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(4 years from now) | |
| US8592462 | LEGACY PHARMA | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US8753679 | LEGACY PHARMA | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(8 months from now) | |
| US8609701 | LEGACY PHARMA | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US8648098 | LEGACY PHARMA | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(4 years from now) | |
| US7635707 | LEGACY PHARMA | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US10188637 | LEGACY PHARMA | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 15 October, 2014
Dosage: TABLET
How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage
ESBRIET family patents
